… When people stop smoking they experience cravings to smoke and unpleasant mood
changes. Nicotine receptor partial agonists aim to reduce these withdrawal symptoms and the …

… We sought to develop a nicotinic receptor partial agonist of the α4β2 nAChR for smoking
cessation. It was hypothesized that an effective agent would, through its intrinsic partial …

… Nicotine receptor partial agonists may help people to stop smoking by a combination of …
Nicotine receptor partial agonists (NRPAs) are a type of medication used to help people to …

… The nicotinic receptor partial agonists, which are currently at different stages of development,
are based on our current knowledge of the neurobiology of tobacco dependence and …

… Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. … a novel,
selective nicotinic receptor partial agonist developed specifically for smoking cessation. This study …

… in nicotine dependence and craving. Varenicline and other selective nicotinic acetylcholine
receptor partial agonists … , but to a lesser extent than nicotine. In line with this mechanism of …

… not based on nicotine. Varenicline, a partial agonist at nicotine receptors, gained US
regulatory approval in 2006 for smoking cessation. Although these agents are all effective for …

… α4β2 nicotinic receptor partial agonist for smoking cessation. … the first nicotinic acetylcholine
receptor partial agonist to be … α4β2 nicotinic receptor partial agonist for smoking cessation. …

… nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation
… show that varenicline is a partial agonist with 45% of nicotine's maximal efficacy at α4β2 …

… that varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor, is an
efficacious smoking cessation pharmacotherapy. The short-term and long-term cessation rate of …